Mikulski, D.; Robak, P.; Perdas, E.; Węgłowska, E.; Łosiewicz, A.; Dróżdż, I.; Jarych, D.; Misiewicz, M.; Szemraj, J.; Fendler, W.;
et al. Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. J. Clin. Med. 2022, 11, 112.
https://doi.org/10.3390/jcm11010112
AMA Style
Mikulski D, Robak P, Perdas E, Węgłowska E, Łosiewicz A, Dróżdż I, Jarych D, Misiewicz M, Szemraj J, Fendler W,
et al. Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. Journal of Clinical Medicine. 2022; 11(1):112.
https://doi.org/10.3390/jcm11010112
Chicago/Turabian Style
Mikulski, Damian, Paweł Robak, Ewelina Perdas, Edyta Węgłowska, Aleksandra Łosiewicz, Izabela Dróżdż, Dariusz Jarych, Małgorzata Misiewicz, Janusz Szemraj, Wojciech Fendler,
and et al. 2022. "Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib" Journal of Clinical Medicine 11, no. 1: 112.
https://doi.org/10.3390/jcm11010112
APA Style
Mikulski, D., Robak, P., Perdas, E., Węgłowska, E., Łosiewicz, A., Dróżdż, I., Jarych, D., Misiewicz, M., Szemraj, J., Fendler, W., & Robak, T.
(2022). Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib. Journal of Clinical Medicine, 11(1), 112.
https://doi.org/10.3390/jcm11010112
